ATC code A10

$11.4 Billion Global Rapid Acting Insulin Market (2021 to 2027) - Industry Analysis Report and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021
Health, Pharmaceutical, Branches of biology, Clinical medicine, Endocrine system, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Intensive insulin therapy, ATC code A10

A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.

Key Points: 
  • A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.
  • By performing rapid-acting insulin opportunity analysis assessment, higher availability of constant glucose tracking will assist in complex analysis of clinic rapid insulin action which was not earlier feasible.
  • Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine.
  • There is a growing case of diabetes and an increasing geriatric population, which is boosting the regional rapid-acting insulin market.

Zealand Pharma presents positive clinical and health economic outcome data with use of regular human insulin delivered by the V-Go in adults with type 2 diabetes

Retrieved on: 
Wednesday, April 15, 2020
Eli Lilly and Company, Branches of biology, RTT, Peptide hormones, Recombinant proteins, Endocrine system, Organ systems, Insulin, Diabetes, Insulin analog, ATC code A10

20045078), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces clinical non-inferiority and positive health economic outcomes with use of regular human insulin (RHI) versus rapid acting insulin (RAI) when delivered by V-Go.

Key Points: 
  • 20045078), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces clinical non-inferiority and positive health economic outcomes with use of regular human insulin (RHI) versus rapid acting insulin (RAI) when delivered by V-Go.
  • Health economic outcomes will be published online in April in the Journal of Managed Care & Specialty Pharmacy supplement.
  • These results show that V-Go may allow diabetes patients to achieve their treatment goals with more affordable regular human insulin.
  • Insulin lispro, rDNA origin and insulin aspart, rDNA origin averaged for RAI unit cost and insulin human injection and regular human insulin, rDNA origin averaged for RHI unit cost.